Overview

The Gene Replacement Therapy by rAAV2/8-hCYP4V2

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Primary Objectives: To evaluate the safety of The Gene Replacement Therapy by rAAV2/8-hCYP4V2 Following a Single Subretinal Administration in The Patients of Bietti's Crystalline Dystrophy (BCD). Secondary Objectives: To explore the efficacy of The Gene Replacement Therapy by rAAV2/8-hCYP4V2.
Phase:
Early Phase 1
Details
Lead Sponsor:
Beijing Tongren Hospital